10x Genomics (TXG) Set to Announce Earnings on Tuesday

10x Genomics (NASDAQ:TXG - Get Free Report) will be announcing its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. 10x Genomics has set its FY 2024 guidance at EPS.Persons that wish to listen to the company's earnings conference call can do so using this link.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.15. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.23%. The business had revenue of $153.10 million for the quarter, compared to the consensus estimate of $150.90 million. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

Shares of NASDAQ:TXG traded down $0.23 during trading hours on Tuesday, hitting $15.14. The company's stock had a trading volume of 1,569,966 shares, compared to its average volume of 1,698,409. The firm's fifty day moving average price is $21.00 and its 200 day moving average price is $22.39. 10x Genomics has a 52 week low of $14.02 and a 52 week high of $57.90. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -6.79 and a beta of 1.85.

Insiders Place Their Bets

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,351 shares of 10x Genomics stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the completion of the transaction, the insider now owns 345,704 shares of the company's stock, valued at approximately $7,788,711.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other 10x Genomics news, CEO Serge Saxonov sold 6,749 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $152,054.97. Following the transaction, the chief executive officer now directly owns 882,467 shares of the company's stock, valued at $19,881,981.51. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 4,351 shares of the business's stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $98,028.03. Following the sale, the insider now directly owns 345,704 shares of the company's stock, valued at $7,788,711.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,061 shares of company stock valued at $316,794. Company insiders own 10.03% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on TXG. Wolfe Research reaffirmed a "peer perform" rating on shares of 10x Genomics in a research report on Thursday, June 27th. Jefferies Financial Group upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating and set a $24.00 target price for the company in a report on Monday, July 22nd. Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $32.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, October 10th. Guggenheim reiterated a "neutral" rating on shares of 10x Genomics in a research note on Tuesday, June 25th. Finally, Stephens reaffirmed an "overweight" rating and issued a $30.00 price target on shares of 10x Genomics in a report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of "Moderate Buy" and an average target price of $30.60.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.